Zinc transporter (ZnT)8186–194 is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients

[1]  Tao Yang,et al.  Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays , 2012, Autoimmunity.

[2]  N. Ahmed,et al.  Antibodies Recognizing Mycobacterium avium paratuberculosis Epitopes Cross-React with the Beta-Cell Antigen ZnT8 in Sardinian Type 1 Diabetic Patients , 2011, PloS one.

[3]  C. Boitard,et al.  Beyond the hormone: insulin as an autoimmune target in type 1 diabetes. , 2011, Endocrine reviews.

[4]  Liping Yu,et al.  Human Type 1 Diabetes Is Associated with T Cell Autoimmunity to Zinc Transporter 8 , 2011, The Journal of Immunology.

[5]  J. Drijfhout,et al.  CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. , 2008, The Journal of clinical investigation.

[6]  P. van Endert,et al.  The Frequency and Immunodominance of Islet-Specific CD8+ T-cell Responses Change after Type 1 Diabetes Diagnosis and Treatment , 2008, Diabetes.

[7]  Marian Rewers,et al.  The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes , 2007, Proceedings of the National Academy of Sciences.

[8]  M. Dolz,et al.  Immunization of HLA Class I Transgenic Mice Identifies Autoantigenic Epitopes Eliciting Dominant Responses in Type 1 Diabetes Patients1 , 2007, The Journal of Immunology.

[9]  M. Dolz,et al.  CD8+ T-Cell Responses Identify β-Cell Autoimmunity in Human Type 1 Diabetes , 2007, Diabetes.

[10]  H. Luthra,et al.  HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis , 1996, The Journal of experimental medicine.